Study design
toxicity, T1c-T2, dosimetric/HA-spacer, CRS
In this Swedish single-center phase II study (NoHarm), 81 patients with low- and intermediate-risk PC were included between 2010 and 2016. Inclusion criteria were < 75 years of age, T1c-T2, Gleason ≤ 6 and PSA < 10 ng/mL, T1c- T3a with 1 or 2 of the following risk factors; T2c-T3a or Gleason ≥ 7 or PSA ≥ 10 ng/mL with WHO performance status 0–2 Additional file Here, we present the results consisting of dosimetric/HA-spacer analysis and toxicity/PRO evaluation. Sixty-six patients were eligible for the toxicity analysis, 64 patients for PRO evaluation and 52 for dosimetric/HA-spacer evaluation; see Fig. Inclusion/exclusion criteria. CRS = CTV-rectum space, HA = Hyaluronic acid, PRO = patient-reported outcome